Bexagliflozin
An SGLT2 inhibitor used to improve blood sugar control in adults with type 2 diabetes by causing the kidneys to excrete excess glucose in the urine. It also has beneficial effects on blood pressure and body weight. Like other drugs in its class, it carries a risk of urinary and genital tract infections.
分子量
464.9000 g/mol
LogP
2.40
TPSA
109.00 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
二维结构
Cite this structure
Embed this structure
SMILES
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1
Molecular Formula
C24H29ClO7
HBD / HBA
4 / 7
可旋转键数
9
重原子数
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
An SGLT2 inhibitor used to improve blood sugar control in adults with type 2 diabetes by causing the kidneys to excrete excess glucose in the urine. It also has beneficial effects on blood pressure and body weight. Like other drugs in its class, it carries a risk of urinary and genital tract infections.
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Yes, Bexagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1808388. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25195624. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bexagliflozin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bexagliflozin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bexagliflozin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bexagliflozin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bexagliflozin"></drugfyi-drug>